{"filing":{"accession_number":"0001104659-26-080501","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"tm2619779d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926080501/tm2619779d1_8k.htm"},"events":[{"id":16055,"run_id":14319,"accession_number":"0001104659-26-080501","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"summary":"While the Tenth Amendment technically amends an existing credit facility rather than creating new debt, the substance reveals severe financial distress: the company capitalized accrued interest into principal, deferred a $9M+ payment, reduced minimum liquidity covenants, and agreed to pursue asset sales or restructuring by July 31, 2026. The lender-controlled strategic committee and extensive operational restrictions signal covenant renegotiation under duress. This is more accurately characterized as a covenant_breach or restructuring event, but the 8-K Item 1.01 classification and the amendment's material modification of debt terms place it closest to debt_issuance in the taxonomy, though covenant_breach may be more precise if the original covenant was breached.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14008,"accession_number":"0001104659-26-080501","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"While the Tenth Amendment technically amends an existing credit facility rather than creating new debt, the substance reveals severe financial distress: the company capitalized accrued interest into principal, deferred a $9M+ payment, reduced minimum liquidity covenants, and agreed to pursue asset sales or restructuring by July 31, 2026. The lender-controlled strategic committee and extensive operational restrictions signal covenant renegotiation under duress. This is more accurately characterized as a covenant_breach or restructuring event, but the 8-K Item 1.01 classification and the amendment's material modification of debt terms place it closest to debt_issuance in the taxonomy, though covenant_breach may be more precise if the original covenant was breached.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T10:06:20.019795+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14008,"accession_number":"0001104659-26-080501","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.35,"reasoning":"While the Tenth Amendment technically amends an existing credit facility rather than creating new debt, the substance reveals severe financial distress: the company capitalized accrued interest into principal, deferred a $9M+ payment, reduced minimum liquidity covenants, and agreed to pursue asset sales or restructuring by July 31, 2026. The lender-controlled strategic committee and extensive operational restrictions signal covenant renegotiation under duress. This is more accurately characterized as a covenant_breach or restructuring event, but the 8-K Item 1.01 classification and the amendment's material modification of debt terms place it closest to debt_issuance in the taxonomy, though covenant_breach may be more precise if the original covenant was breached.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T10:06:20.019795+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-07-06"}]}